$CDXS
CODEXIS, INC.

2014 Q2 Form 10-Q Financial Statement

#000120037514000021 Filed on May 08, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q1
Revenue $6.570M $7.074M $11.48M
YoY Change -5.79% -38.39% -63.13%
Cost Of Revenue $2.123M $2.524M $5.665M
YoY Change -41.53% -55.45% -55.19%
Gross Profit $4.447M $4.550M $5.816M
YoY Change 33.02% -21.77% -68.55%
Gross Profit Margin 67.69% 64.32% 50.66%
Selling, General & Admin $5.625M $6.112M $8.124M
YoY Change -21.54% -24.77% -13.53%
% of Gross Profit 126.49% 134.33% 139.68%
Research & Development $7.733M $4.834M $7.322M
YoY Change -10.33% -33.98% -55.21%
% of Gross Profit 173.89% 106.24% 125.89%
Depreciation & Amortization $1.910M $1.016M $1.798M
YoY Change -26.25% -43.49% -18.38%
% of Gross Profit 42.95% 22.33% 30.91%
Operating Expenses $15.48M $13.47M $21.11M
YoY Change -20.3% -36.19% -45.0%
Operating Profit -$8.911M -$6.396M -$9.630M
YoY Change -28.43% -33.58% 32.83%
Interest Expense $0.00 $10.00K $30.00K
YoY Change -100.0% -66.67% -62.5%
% of Operating Profit
Other Income/Expense, Net $8.000K $118.0K $85.00K
YoY Change -95.63% 38.82% -27.97%
Pretax Income -$8.916M -$6.505M -$9.688M
YoY Change -29.33% -32.86% 32.84%
Income Tax -$437.0K -$130.0K -$65.00K
% Of Pretax Income
Net Earnings -$8.479M -$6.375M -$9.623M
YoY Change -32.73% -33.75% 28.48%
Net Earnings / Revenue -129.06% -90.12% -83.82%
Basic Earnings Per Share
Diluted Earnings Per Share -$223.3K -$165.7K -$254.2K
COMMON SHARES
Basic Shares Outstanding 38.66M shares 38.40M shares 38.01M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.09M $24.17M $44.18M
YoY Change -47.0% -45.3% -17.12%
Cash & Equivalents $20.09M $23.16M $31.23M
Short-Term Investments $0.00 $1.002M $12.94M
Other Short-Term Assets $1.900M $3.100M $4.100M
YoY Change -17.39% -24.39% 0.0%
Inventory $1.963M $2.045M $1.686M
Prepaid Expenses
Receivables $2.944M $4.907M $7.412M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $26.91M $34.24M $57.37M
YoY Change -37.58% -40.31% -28.91%
LONG-TERM ASSETS
Property, Plant & Equipment $4.853M $7.396M $14.79M
YoY Change -68.73% -50.0% -38.37%
Goodwill $3.241M $3.241M $3.241M
YoY Change 0.0% 0.0%
Intangibles $7.873M $8.716M $12.09M
YoY Change -30.0% -27.91%
Long-Term Investments $1.500M $1.400M $1.900M
YoY Change 50.0% -26.32% -78.65%
Other Assets $205.0K $208.0K $2.701M
YoY Change -43.53% -92.3% 17.43%
Total Long-Term Assets $18.34M $21.72M $36.27M
YoY Change -43.58% -40.13% -32.7%
TOTAL ASSETS
Total Short-Term Assets $26.91M $34.24M $57.37M
Total Long-Term Assets $18.34M $21.72M $36.27M
Total Assets $45.24M $55.96M $93.64M
YoY Change -40.16% -40.24% -30.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.329M $3.487M $4.445M
YoY Change 115.47% -21.55% -50.61%
Accrued Expenses $2.833M $2.699M $4.826M
YoY Change -27.36% -44.07% -68.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.79M $13.09M $17.78M
YoY Change -3.15% -26.36% -46.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.214M $4.900M $3.868M
YoY Change 11.39% 26.68% -24.16%
Total Long-Term Liabilities $4.214M $4.900M $3.868M
YoY Change 11.39% 26.68% -24.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.79M $13.09M $17.78M
Total Long-Term Liabilities $4.214M $4.900M $3.868M
Total Liabilities $15.92M $19.39M $21.64M
YoY Change 6.61% -10.42% -43.49%
SHAREHOLDERS EQUITY
Retained Earnings -$271.7M -$263.2M -$225.2M
YoY Change 14.27% 16.9%
Common Stock $4.000K $4.000K $4.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.33M $36.57M $70.75M
YoY Change
Total Liabilities & Shareholders Equity $45.24M $55.96M $93.64M
YoY Change -40.16% -40.24% -30.43%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$8.479M -$6.375M -$9.623M
YoY Change -32.73% -33.75% 28.48%
Depreciation, Depletion And Amortization $1.910M $1.016M $1.798M
YoY Change -26.25% -43.49% -18.38%
Cash From Operating Activities -$3.930M -$2.405M -$3.487M
YoY Change -44.41% -31.03% -688.03%
INVESTING ACTIVITIES
Capital Expenditures -$90.00K $21.00K $48.00K
YoY Change -84.75% -56.25% -97.72%
Acquisitions
YoY Change
Other Investing Activities $1.060M $3.630M $2.500M
YoY Change -87.97% 45.2% 19.05%
Cash From Investing Activities $970.0K $3.606M $2.452M
YoY Change -88.2% 47.06% -27344.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -110.0K -$168.0K $263.0K
YoY Change -650.0% -163.88% 179.79%
NET CHANGE
Cash From Operating Activities -3.930M -$2.405M -$3.487M
Cash From Investing Activities 970.0K $3.606M $2.452M
Cash From Financing Activities -110.0K -$168.0K $263.0K
Net Change In Cash -3.070M $1.033M -$772.0K
YoY Change -362.39% -233.81% -213.86%
FREE CASH FLOW
Cash From Operating Activities -$3.930M -$2.405M -$3.487M
Capital Expenditures -$90.00K $21.00K $48.00K
Free Cash Flow -$3.840M -$2.426M -$3.535M
YoY Change -40.74% -31.37% 133.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3487000 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3961000 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5413000 USD
CY2014Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4907000 USD
CY2013Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
43000 USD
CY2014Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1000 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1612000 USD
CY2014Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2699000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
29461000 USD
CY2014Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
29678000 USD
CY2014Q1 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
370000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-32000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-32000 USD
CY2014Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
370000 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
298370000 USD
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
299431000 USD
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
460000 USD
CY2014Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
460000 USD
CY2013Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
844000 USD
CY2014Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
844000 USD
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7526000 shares
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7158000 shares
CY2013Q4 us-gaap Asset Impairment Charges
AssetImpairmentCharges
1571000 USD
CY2014Q1 us-gaap Asset Retirement Obligation
AssetRetirementObligation
109000 USD
CY2013Q4 us-gaap Assets
Assets
58840000 USD
CY2014Q1 us-gaap Assets
Assets
55959000 USD
CY2014Q1 us-gaap Assets Current
AssetsCurrent
34241000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
35781000 USD
CY2013Q4 us-gaap Assets Held For Sale At Carrying Value
AssetsHeldForSaleAtCarryingValue
2179000 USD
CY2014Q1 us-gaap Assets Held For Sale At Carrying Value
AssetsHeldForSaleAtCarryingValue
1394000 USD
CY2014Q1 us-gaap Assets Held For Sale Current
AssetsHeldForSaleCurrent
1394000 USD
CY2013Q4 us-gaap Assets Held For Sale Current
AssetsHeldForSaleCurrent
2179000 USD
CY2014Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
17040000 USD
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
19889000 USD
CY2014Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
16156000 USD
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
19654000 USD
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5973000 USD
CY2014Q1 us-gaap Cash
Cash
8571000 USD
CY2013Q4 us-gaap Cash
Cash
6041000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22130000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23163000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31231000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32003000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1033000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-772000 USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38661000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38351000 shares
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38661000 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38351000 shares
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9431000 USD
CY2014Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, accounts receivable and restricted cash. Cash and cash equivalents, marketable securities and restricted cash are invested through banks and other financial institutions in the United States, as well as in other foreign countries. Such deposits may be in excess of insured limits.</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk with respect to accounts receivable exists to the extent of amounts presented in the condensed consolidated financial statements. The Company estimates an allowance for doubtful accounts through specific identification of potentially uncollectible accounts receivable based on an analysis of its accounts receivable aging. Uncollectible accounts receivable are written off against the allowance for doubtful accounts when all efforts to collect them have been exhausted. Recoveries are recognized when they are received. Actual collection losses may differ from its estimates and could be material to its consolidated financial position, results of operations, and cash flows.</font></div></div>
CY2014Q1 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.10
CY2013Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5665000 USD
CY2014Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
2524000 USD
CY2014Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3266000 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2001000 USD
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1114000 USD
CY2014Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1398000 USD
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1798000 USD
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1016000 USD
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2014Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3638000 USD
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3625000 USD
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1783000 USD
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M13D
CY2014Q1 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
1.00
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
15316000 USD
CY2014Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
16160000 USD
CY2014Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2530000 USD
CY2014Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2812000 USD
CY2014Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3374000 USD
CY2014Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
24876000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
24876000 USD
CY2014Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8716000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9560000 USD
CY2014Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
66000 USD
CY2013Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-108000 USD
CY2013Q1 us-gaap Gain Or Loss On Sale Of Stock In Subsidiary
GainOrLossOnSaleOfStockInSubsidiary
0 USD
CY2014Q1 us-gaap Gain Or Loss On Sale Of Stock In Subsidiary
GainOrLossOnSaleOfStockInSubsidiary
760000 USD
CY2013Q4 us-gaap Goodwill
Goodwill
3241000 USD
CY2014Q1 us-gaap Goodwill
Goodwill
3241000 USD
CY2013Q1 us-gaap Goodwill
Goodwill
3241000 USD
CY2013 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2014Q1 us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0 USD
CY2013Q1 us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0 USD
CY2014Q1 us-gaap Incentive From Lessor
IncentiveFromLessor
2054000 USD
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-9688000 USD
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-6505000 USD
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-65000 USD
CY2013Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2197000 USD
CY2014Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1279000 USD
CY2013Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
464000 USD
CY2014Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-8000 USD
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-130000 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
792000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-472000 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-133000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-550000 USD
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2120000 USD
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1549000 USD
CY2013Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
656000 USD
CY2014Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
162000 USD
CY2013Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
384000 USD
CY2014Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
557000 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
813000 USD
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1301000 USD
CY2014Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8716000 USD
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9560000 USD
CY2013Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
693000 USD
CY2014Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1359000 USD
CY2014Q1 us-gaap Inventory Net
InventoryNet
2045000 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
1487000 USD
CY2014Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
577000 USD
CY2013Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
763000 USD
CY2014Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
109000 USD
CY2013Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
31000 USD
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
27000 USD
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
9000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
17357000 USD
CY2014Q1 us-gaap Liabilities
Liabilities
19388000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58840000 USD
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55959000 USD
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
13090000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11199000 USD
CY2014Q1 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
600000 USD
CY2014Q1 us-gaap Marketable Securities
MarketableSecurities
1002000 USD
CY2013Q4 us-gaap Marketable Securities
MarketableSecurities
3005000 USD
CY2013Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
795000 USD
CY2014Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1446000 USD
CY2013Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
16089000 USD
CY2014Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
14592000 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
13470000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6396000 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9630000 USD
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
16043000 USD
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2736000 USD
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2677000 USD
CY2014Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Codexis, Inc. (the &#8220;Company&#8221;) was incorporated in the State of Delaware in January 2002. The Company develops biocatalysts for the pharmaceutical and fine chemicals market. Its proven technologies enable scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development, from research to manufacturing. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Biocatalysts are enzymes or microbes that initiate and/or accelerate chemical reactions. Manufacturers have historically used naturally occurring biocatalysts to produce many goods used in everyday life. However, inherent limitations in naturally occurring biocatalysts have restricted their commercial use. The Company&#8217;s proprietary technology platform is able to overcome many of these limitations, allowing us to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has commercialized its technology and products in the pharmaceuticals market, which is the Company&#8217;s primary business focus. The Company&#8217;s pharmaceutical customers, which include several of the largest global pharmaceutical companies, use the Company&#8217;s technology, products and services in their manufacturing process development, including in the production of some of the world's bestselling and fastest growing drugs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has recently begun to use its technology to develop biocatalysts for use in the fine chemicals market. The fine chemicals market is similar to the Company&#8217;s pharmaceutical business and consists of several large market segments, including food, animal feed, polymers, flavors and fragrances and agricultural chemicals.</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company creates its biocatalyst products by applying its CodeEvolver</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> directed evolution technology platform, which introduces genetic mutations into microorganisms, giving rise to changes in the enzymes that they produce. Once the Company identifies potentially beneficial mutations, it tests combinations of these mutations until it has created variant enzymes that exhibit marketable performance characteristics superior to competitive products. This process allows the Company to make continuous, efficient improvements to the performance of its enzymes.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In these Notes to Consolidated Financial Statements, the &#8220;Company&#8221; refers to Codexis, Inc. and its subsidiaries on a consolidated basis.</font></div></div>
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-168000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
263000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3606000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2452000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3487000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2405000 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-9623000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-6375000 USD
CY2014Q1 us-gaap Noncurrent Assets
NoncurrentAssets
16320000 USD
CY2013Q4 us-gaap Noncurrent Assets
NoncurrentAssets
18312000 USD
CY2014Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 operating_segment
CY2014Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 reporting_unit
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
21111000 USD
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2827000 USD
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2743000 USD
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
3054000 USD
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
2006000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
306000 USD
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
208000 USD
CY2014Q1 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
402000 USD
CY2013Q1 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
192000 USD
CY2014Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
401000 USD
CY2014Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
1000 USD
CY2014Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
401000 USD
CY2013Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
123000 USD
CY2014Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
248000 USD
CY2013Q1 us-gaap Other Expenses
OtherExpenses
85000 USD
CY2014Q1 us-gaap Other Expenses
OtherExpenses
118000 USD
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5044000 USD
CY2014Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4900000 USD
CY2013Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 USD
CY2014Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
230000 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000 USD
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48000 USD
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1567000 USD
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1730000 USD
CY2014Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1500000 USD
CY2013Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
CY2013Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2500000 USD
CY2014Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2000000 USD
CY2014Q1 us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
10000 USD
CY2013Q1 us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
0 USD
CY2014Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
117000 USD
CY2013Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2014Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
779000 USD
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
62000 USD
CY2013Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
263000 USD
CY2014Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37066000 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37866000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8446000 USD
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7396000 USD
CY2013Q1 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
1300000 USD
CY2014Q1 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
2146000 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4834000 USD
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7322000 USD
CY2014Q1 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
711000 USD
CY2013Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
711000 USD
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-263234000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-256859000 USD
CY2014Q1 us-gaap Revenues
Revenues
7074000 USD
CY2013Q1 us-gaap Revenues
Revenues
11481000 USD
CY2014Q1 us-gaap Royalty Revenue
RoyaltyRevenue
1943000 USD
CY2013Q1 us-gaap Royalty Revenue
RoyaltyRevenue
1044000 USD
CY2013Q1 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
9137000 USD
CY2014Q1 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
2985000 USD
CY2013Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8124000 USD
CY2014Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6112000 USD
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1472000 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1229000 USD
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
41483000 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
36571000 USD
CY2014Q1 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
402000 USD
CY2013Q1 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
192000 USD
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company's management regularly assesses these estimates which primarily affect revenue recognition, the valuation of marketable securities and accounts receivable, held for sale assets, intangible assets, goodwill arising out of business acquisitions, inventories, accrued liabilities, stock awards and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements.</font></div></div>
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37842000 shares
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38506000 shares
CY2014Q1 cdxs Availableforsale Securities Accumulated Gross Unrealized Gainbefore Tax
AvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax
884000 USD
CY2013Q4 cdxs Availableforsale Securities Accumulated Gross Unrealized Gainbefore Tax
AvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax
235000 USD
CY2014Q1 cdxs Availableforsale Securities Accumulated Gross Unrealized Lossbefore Tax
AvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax
0 USD
CY2013Q4 cdxs Availableforsale Securities Accumulated Gross Unrealized Lossbefore Tax
AvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax
0 USD
CY2014Q1 cdxs Maturity Date Of Highly Liquid Investments
MaturityDateOfHighlyLiquidInvestments
P3M
CY2013Q4 cdxs Number Of Marketable Securities
NumberOfMarketableSecurities
0 securities
CY2014Q1 cdxs Number Of Marketable Securities
NumberOfMarketableSecurities
0 securities
CY2013Q4 cdxs Property Plantand Equipment Net Excluding Constructionin Progress
PropertyPlantandEquipmentNetExcludingConstructioninProgress
8405000 USD
CY2014Q1 cdxs Property Plantand Equipment Net Excluding Constructionin Progress
PropertyPlantandEquipmentNetExcludingConstructioninProgress
7388000 USD
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001200375
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38660773 shares
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
CODEXIS INC

Files In Submission

Name View Source Status
0001200375-14-000021-index-headers.html Edgar Link pending
0001200375-14-000021-index.html Edgar Link pending
0001200375-14-000021.txt Edgar Link pending
0001200375-14-000021-xbrl.zip Edgar Link pending
cdxs-20140331.xml Edgar Link completed
cdxs-20140331.xsd Edgar Link pending
cdxs-20140331_cal.xml Edgar Link unprocessable
cdxs-20140331_def.xml Edgar Link unprocessable
cdxs-20140331_lab.xml Edgar Link unprocessable
cdxs-20140331_pre.xml Edgar Link unprocessable
cdxs_20140331x10q.htm Edgar Link pending
cdxs_20140331xex311.htm Edgar Link pending
cdxs_20140331xex312.htm Edgar Link pending
cdxs_20140331xex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending